Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.32 |
| ▸ | DRD2 | P14416 | 4/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | UBE2M | P61081 | 1/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762461 | 0.82 | HSD11B1 (0.37) | KCNH2 | |
| SCHEMBL23434542 | 0.80 | CYP3A4 (0.33) | CHRM4CYP3A4UBE2MDCUN1D1OPRM1 | |
| SCHEMBL22006210 | 0.80 | LTA4H (0.37) | CHRM4CYP3A4UBE2MDCUN1D1OPRM1 | |
| SCHEMBL9924112 | 0.79 | CHRM4 (0.31) | CHRM4UBE2MDCUN1D1 | |
| SCHEMBL22624169 | 0.79 | TERT (0.32) | TERT | |
| SCHEMBL22006211 | 0.78 | ALDH1A1 (0.39) | — | |
| SCHEMBL13212683 | 0.78 | LTA4H (0.36) | CYP3A4 | |
| SCHEMBL5184021 | 0.77 | SMN1; SMN2 (0.42) | TERTDRD3KCNH2DRD2UBE2M | |
| SCHEMBL5184024 | 0.77 | SMN1; SMN2 (0.42) | TERTDRD3KCNH2DRD2UBE2M | |
| SCHEMBL12665789 | 0.76 | HTR7 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| US-9206200-B2 | N-linked lactam M1 receptor positive allosteric mogulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2015-03-05 | — | — | US | disclosed |
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | disclosed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293674-A1 | Azinyl Imidazoazine and Azinyl Carboxamide | BAYER CROPSCIENCE AG (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293674-A1 | Azinyl Imidazoazine and Azinyl Carboxamide | AZI2, NISCH, ZYX | TERT 1134/4885DRD3 923/4885KCNH2 885/4885 |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | TERT 4836/4885DRD3 322/4885KCNH2 3123/4885 |
| US-20150065498-A1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | TERT 4413/4885DRD3 1057/4885KCNH2 1761/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | TERT 4424/4885DRD3 4122/4885KCNH2 1935/4885 |
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | TERT 1088/4885DRD3 2495/4885KCNH2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.